Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Syncom Formulations reported annual standalone revenue of Rs 48,657.28 Lacs for FY2026, up 5.1% from Rs 46,284.93 Lacs in FY2025. Profit After Tax (PAT) grew significantly by 55.5% to Rs 7,600.80 Lacs from Rs 4,887.18 Lacs. Basic EPS improved from Rs 0.52 to Rs 0.81. The company operates in three segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The auditors issued an unmodified (clean) opinion with no qualifications. Note 9 discloses that EPS was restated because the company corrected its calculation methodology to comply with Ind AS 33 (previously used Total Comprehensive Income instead of PAT). An additional disclosure notes an incremental labor cost of Rs 87.81 Lacs due to new Labour Codes effective November 2025.
Strong PAT growth of 55% with clean audit opinion is positive for shareholders. The EPS restatement is a housekeeping correction that does not affect actual cash flows or business performance. Revenue growth of 5% is modest but improving profitability indicates better operational efficiency.